Alpelisib and fulvestrant for advanced breast cancer: SOLAR-1

Bookmark and Share
Published: 20 Oct 2018
Views: 3620
Prof Fabrice André - Institut Gustave Roussy, Paris, France

Prof Fabrice André presents data at the ESMO 2018 congress in Munich from a phase III combination therapy trial including a targeted PI3K inhibitor to treat men and post-menopausal women with advanced breast cancer.

For more on these findings, watch his interview with ecancer here.